Department of Nephrology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Research Center for Environmental Determinants of Health (RCEDH), School of Public Health, Kermanshah Uninversity of Medical Sciences, Kermanshah, Iran.
Curr Pharm Des. 2019;25(9):1021-1029. doi: 10.2174/1381612825666190215123759.
Prostate cancer is the most common malignant cancer in men worldwide and after lung cancer, it is the second leading cause of cancer mortality in men. The purpose of this study was to investigate the relationship between prostate cancer and metformin consumption in men.
The current study is a systematic and meta-analysis review based on the PRISMA statement. To access the studies of domestic and foreign databases, Iran Medex, SID, Magiran, Iran Doc, Medlib, ProQuest, Science Direct, PubMed, Scopus, Web of Science and the Google Scholar search engine were searched during the 2009- 2018 period for related keywords. In order to evaluate the heterogeneity of the studies, Q test and I2 indicator were used. The data were analyzed using the STATA 15.1 software.
In 11 studies with a sample size of 877058, the odds ratio of metformin consumption for reducing prostate cancer was estimated at 0.89 (95%CI: 0.67-1.17). Meta-regression also showed there was no significant relationship between the odds ratio and the publication year of the study. However, there was a significant relationship between the odds ratio and the number of research samples.
Using metformin in men reduces the risk of prostate cancer but it is not statistically significant.
前列腺癌是全球男性中最常见的恶性肿瘤，仅次于肺癌，是男性癌症死亡的第二大主要原因。本研究旨在探讨男性前列腺癌与二甲双胍消费之间的关系。
本研究是基于 PRISMA 声明的系统评价和荟萃分析。为了获取国内外数据库的研究，在 2009 年至 2018 年期间，使用伊朗 Medex、SID、Magiran、Iran Doc、Medlib、ProQuest、Science Direct、PubMed、Scopus、Web of Science 和 Google Scholar 搜索引擎检索了相关关键字。为了评估研究的异质性，使用了 Q 检验和 I2 指标。使用 STATA 15.1 软件对数据进行分析。
在 11 项样本量为 877058 的研究中，二甲双胍消费降低前列腺癌风险的优势比估计为 0.89（95%CI：0.67-1.17）。元回归也表明，优势比与研究的发表年份之间没有显著关系。然而，优势比与研究样本数量之间存在显著关系。
男性使用二甲双胍可降低前列腺癌的风险，但无统计学意义。
